ArticleJournal of clinical laboratory analysis2020
Up-regulation of long non-coding RNA THRIL in coronary heart disease: Prediction for disease risk, correlation with inflammation, coronary artery stenosis, and major adverse cardiovascular events.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Diagnostic and prognostic significance of lncRNA THRIL in gestational diabetes mellitus and the regulation of trophoblastic function.Irish journal of medical science · 2025Article
- The role of long non-coding RNAs in cardiovascular diseases: A comprehensive review.Non-coding RNA research · 2025Review
- A Real-Time Computer-Aided Diagnosis System for Coronary Heart Disease Prediction Using Clinical Information.Reviews in cardiovascular medicine · 2025Article
- Sequential changes in expression of long non-coding RNAs THRIL and MALAT1 after ischemic stroke.Current journal of neurology · 2024Article
- Association of Long Noncoding RNA Expression Signatures with Stress-Induced Myocardial Perfusion Defects.Biomolecules · 2023Article
- Differential Expression of LOXL1-AS1 in Coronary Heart Disease and its Regulatory Mechanism in ox-LDL-Induced Human Coronary Artery Endothelial Cell Pyroptosis.Cardiovascular drugs and therapy · 2023Article
- Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury.Genes & diseases · 2022Review
- Diagnostic and prognostic significance of lncRNA SOX2-OT in patients with carotid atherosclerosis.BMC cardiovascular disorders · 2022Article
- LncRNA THRIL promotes high glucose-induced proliferation and migration of human retina microvascular endothelial cells through enhancing autophagy.Acta diabetologica · 2022Article
- Increased mortality in the A/A genotype of the SNP rs28372698 of interleukin 32.Experimental and therapeutic medicine · 2021Article
- The Emerging Role of Long Non-coding RNAs and Circular RNAs in Coronary Artery Disease.Frontiers in cardiovascular medicine · 2021Review
- The Role of Long Non-coding RNAs in Sepsis-Induced Cardiac Dysfunction.Frontiers in cardiovascular medicine · 2021Review
- Up-regulation of long non-coding RNA THRIL in coronary heart disease: Prediction for disease risk, correlation with inflammation, coronary artery stenosis, and major adverse cardiovascular events.Journal of clinical laboratory analysis · 2020Article
- The expression patterns of MALAT-1, NEAT-1, THRIL, and miR-155-5p in the acute to the post-acute phase of COVID-19 disease.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
- Clinical significance of LINC00893 and miR-103a-3p in type 2 diabetes mellitus patients with coronary heart disease.Diabetes & vascular disease researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the role of long non-coding RNA (lncRNA) THRIL in coronary heart disease (CHD) patients.
methodsA total of 420 patients who underwent coronary arteriography due to suspected symptoms of CHD were enrolled, in which 220 were diagnosed as CHD and 200 were set as control subjects. LncRNA THRIL in plasma samples of CHD patients and control subjects was detected by reverse transcription-quantitative polymerase chain reaction. Gensini score and biochemical indexes were evaluated in CHD patients and control subjects. Plasma inflammatory cytokines were detected, and major adverse cardiovascular events (MACE) were recorded in CHD patients.
resultsBoth before and after adjustment by age/gender, lncRNA THRIL was increased in CHD patients compared with control subjects (both P < .001), and it well predicted enhanced CHD risk by receiver operating characteristic curves. For coronary artery stenosis, it was positively correlated with Gensini score (P < .001, r = .430). For clinical characteristics, lncRNA THRIL was positively correlated with diabetes mellitus occurrence (P < .001) and fasting blood glucose (FBG) level (P = .029, r = .147). For inflammation, it was positively associated with CRP (P < .001, r = .374), TNF-α (P < .001, r = .249), IL-1β (P = .001, r = .222), IL-8 (P < .001, r = .254), and IL-17 (P = .011, r = .172), while negatively correlated with IL-10 (P < .001, r = -.244). For prognosis, lncRNA THRIL was positively associated with MACE accumulating rate (P = .037) in CHD patients.
conclusionLong non-coding RNA THRIL was increased in CHD patients and well predicted elevated CHD risk. Moreover, it was correlated with enhanced coronary stenosis, systematic inflammation, FBG level, and MACE risk in CHD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.